Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biopsy-based mechanistic study of ianalumab in Sjögren's syndrome
2023-508957-24-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ianalumab in Sjögren's syndrome, sponsored by Novartis. Primary endpoint: Change from baseline in logarithm of salivary gland B/B+T cell ratio at Week 25 (end of treatment). Started Mar 2024; status: completed.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2023-508957-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508957-24-00.